CLINICAL AND ECONOMIC BURDEN ATTRIBUTABLE TO SEROTYPES INCLUDED IN FUTURE PNEUMOCOCCAL CONJUGATE VACCINES IN CANADIAN CHILDREN UNDER FIVE YEARS OF AGE (ID 236)
- Johnna Perdrizet, United States of America
- Johnna Perdrizet, United States of America
- Marie Claude Breton, Canada
- Jelena Vojicic, Canada
- Matt Wasserman, United States of America
Abstract
Background
In Canada, higher-valence pneumococcal conjugate vaccines (PCV10, PCV13) were introduced into the routine pediatric programs in 2009/2010. Despite their impact, there remains substantial disease burden. PCVs inclusive of up to 20 serotypes (PCV20), currently in development, are expected to considerably expand pneumococcal disease coverage. Our objective was to estimate the clinical and economic burden caused by PCV20 serotypes among Canadian children under five years.
Methods
Epidemiologic, clinical, and cost data were derived or estimated from published sources (Table 1). Cases (invasive pneumococcal disease (IPD), pneumonia, acute otitis media (AOM)), mortality, and direct costs caused by PCV20 serotypes were calculated for children under 5 based on 2017 population figures and assuming IPD serotype distribution for all clinical entities.
Results
Results are summarized in Table 1. Based on our assumptions, PCV20 serotypes were estimated to cover 52% of pneumococcal disease, or a total of 102,036 annual cases. Of these, IPD represented an estimated 0.13%. Total direct attributable costs were 27 million CAD. 
Conclusions
Substantial amount of morbidity from pneumococcal disease, of which IPD represents only a small proportion, could be potentially addressed by the next generation PCVs currently in development.